Slide 1: Financial highlights Q2 2017
Financial highlights Q2 2017 7 August 2017 SGX:42T OTCQX: TRNLY
Slide 2: Legal disclaimer
Legal disclaimer IMPORTANT NOTICE This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. (“Company”) or any of its portfo
Slide 3: Agenda
Agenda 1. Corporate highlights: Todd Dollinger, Chairman & CEO 2. Financial highlights: Gabi Heller, CFO 3. Portfolio valuation: Steve Rhodes, Chairman & CEO 3
Slide 4: Corporate highlights
Corporate highlights
Slide 5: Key corporate developments Q2 2017
Key corporate developments Q2 2017 • Net profit after tax of US$2.4 million for second quarter. • Increase of 4.7% in portfolio value from 31 December 2016 to US$87.6 million. • Seventh exit completed, BioSight Ltd., with internal rate of return (IRR) of 71%. • Reported confirmation that product of
Slide 6: Financial highlights
Financial highlights
Slide 7: Consolidated condensed report of income
Consolidated condensed report of income Three Months Ended 30 June 2017 30 June 2016 (Unaudited) (Unaudited) US$’000 US$’000 Income: Gain (loss) from change in fair value of investments in portfolio companies 3,776 (4,700) Income from services to portfolio companies 1,133 863 Group's share of losses
Slide 8: Key components of value (US$ million)
Key components of value (US$ million) (1) Israeli government loans are non-recourse loans which only come due upon exit events (2) Deferred taxes are related to unrealized portfolio company valuation profits and are offset and paid only upon realization of cash received upon exits 8
Slide 9: Portfolio valuations
Portfolio valuations
Slide 10: Exit returns: return on investment and IRR
Exit returns: return on investment and IRR Estimated Exit Company/Description Acquirer IRR (%) Return(1) 2017 BioSight Arkin Bio Ventures LP 216.7 X 71 2016 E.T.View Medical Ambu A/S 1.2 X 5 Most Valuable Portfolio 2014 Undisclosed(3) 79.1 X(2) 80 Company (MVPC)(3) 2014 Inspiro Medical OPKO Health 8
Slide 11: Carrying value on eve of exit vs. exit value
Carrying value on eve of exit vs. exit value All exits through 30 June 2017 (US$ thousands) 70 60 50 40 30 20 10 0 Pre-exit carrying value Exit value (1) (1) Includes PV of estimated royalties for Most Valuable Portfolio Company 11
Slide 12: Companies to Watch
10 Companies to Watch* 1. ApiFix Ltd. 6. Fidmi Medical Ltd. 2. Arcuro Ltd. 7. Gordian Surgical Ltd. 3. BioFishency Ltd. 8. Leviticus Cardio Ltd. 4. EdenShield Ltd. 9. MemTech Ltd. 5. Escala Ltd. 10. Vensica Medical Ltd. *Published 5 July 2017 For complete report, go to: 10 Companies to Watch. 12
Slide 13: Contact details
Todd Dollinger, Chairman & CEO SGX: 42T todd@trendlines.com OTCQX: TRNLY Steve Rhodes, Chairman & CEO +972.72.260.7000 steve@trendlines.com www.trendlines.com Gabi Heller, CFO gabi@trendlines.com Judith Kleinman Director IR & Corporate Communications 7 August 2017 judith@trendlines.com